Screener
Allogene Therapeutics ALLO Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's enterprise value?
- Allogene Therapeutics (ALLO) reported enterprise value of $635.27M in Q1 2026.
- How has Allogene Therapeutics's enterprise value changed year-over-year?
- Allogene Therapeutics's enterprise value increased by 79.8% year-over-year, from $353.38M to $635.27M.
- What is the long-term trend for Allogene Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Allogene Therapeutics's enterprise value has grown at a -37.5% compound annual growth rate (CAGR), from $3.46B to $329.15M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Allogene Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude